Inherent variation of increasingly complex in vitro test systems as well as little guidance for routine cell culture reduce the predictive value of cell cultures. Therefore, setting common standards is of ever-increasing importance in view to the high need for comparability and reproducibility of research and development in life sciences. Therefore, standards for “Good Cell Culture Practice (GCCP)” have been put forward by leading scientists in the field, which will facilitate the inter-laboratory comparison of in vitro results.
Evercyte adheres to these GCCP standards
our cells are characterized for expression of markers and functions and show a stable of phenotype over at least 50 population doublings (PDs)
Evercyte offers relevant and high-quality cell lines and in vitro bioassays that are standardized, reliable and will support the harmonization of in vitro cell culture work.
Publications: “Good Cell Culture Practice”
Pamies 2022 https://pubmed.ncbi.nlm.nih.gov/34882777/
Kleensang 2016 https://pubmed.ncbi.nlm.nih.gov/27456714/
Peterson 2019 https://pubmed.ncbi.nlm.nih.gov/31507156/
Evercyte is a biotechnology company focused on the establishment and distribution of human primary like, highly relevant continuously growing cell cultures for use in basic research as well as for the development of pre-clinical test systems, for drug screening / development or for production of extracellular vesicles / exosomes.
(ETS No.164) https://www.coe.int/en/web/conventions/full-list/…
(DSG 2000, Datenschutz-Anpassungsgesetz 2018, DSG 2018)
and risk assessment
Cells are only isolated from donors that are negative for HIV, HepB, HepC and that are clinically unremarkable. After genetic modification of isolated primary cells and subsequent life span extension, the cells are subjected to a detailed characterization including tests for expression of cell type specific markers and functions as well as for detection of viral, bacterial, fungal contaminations and authentication.